Rhythm Pharmaceuticals
IPO
Pioneering a path forward for patients and families.
- Headquarters
- Boston, Massachusetts
- Employees
- 201–500
- Founded
- 2010
- Business Model
- B2B
- Website
- rhythmtx.com
- Total Funding
- $398.0M
- Last Round
- $175.0M Extension RoundJul 2025
About
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases. The company develops precision medicines addressing the root cause of diseases driven by the melanocortin-4 receptor (MC4R) pathway, including its lead asset IMCIVREE (setmelanotide) approved for rare genetic obesity disorders such as Bardet-Biedl syndrome and POMC deficiency. Rhythm trades on Nasdaq under the ticker RYTM.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account